Jan Deland please

Access DB# 110640

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Sabiha Qazi Examiner #: 74141 Date: 12/16/03
Art Unit: 1616 Phone Number 305-3510 Serial Number: 09/779,331
Mail Box and Bldg/Room Location: 2D19 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Anti-angiogenic Agents See 09/939,208

Inventors (please provide full names): AGOSTON, et al

Full name (Gregory E. Agoston)

Earliest Priority Filing Date: 2/8/2002

***For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.**

Please search for the Steroids of Cl II.

If no hits then search for Cl I.

Cl II is more limited at Ra, Rb, Ro

Z', Rg e(1+) 0.1+

Ra is

Thank You

****

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: Lan 4495	NA Sequence (#)_____	STN ✓
Searcher Phone #:	AA Sequence (#)_____	Dialog
Searcher Location:	Structure (#) _____	Questel/Orbit
Date Searcher Picked Up: 12/21/03	Bibliographic _____	Dr.Link
Date Completed: 12.17.03	Litigation _____	Lexis/Nexis
Searcher Prep & Review Time:	Fulltext _____	Sequence Systems
Clerical Prep Time: 20	Patent Family _____	WWW/Internet
Online Time: 430	Other _____	Other (specify)

PTO-1590 (8-01)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 100:68583

=> => fil uspatall
FILE 'USPATFULL' ENTERED AT 11:26:30 ON 21 DEC 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:26:30 ON 21 DEC 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> d l19 bib abs hitstr

L19 ANSWER 1 OF 1 USPATFULL on STN
AN 1999:143299 USPATFULL
TI Selective denial of encrypted high precision data by indirect keying
IN Clark, James Monroe, Verona, NJ, United States
PA ITT Corporation, New York, NY, United States (U.S. corporation)
PI US 5982897 19991109
AI US 1998-95623 19980610 (9)
RLI Continuation of Ser. No. US 1995-429519, filed on 26 Apr 1995, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Hayes, Gail O.; Assistant Examiner: Sayadian, Hrayr A.
LREP Plevy, Arthur L.
CLMN Number of Claims: 24
ECL Exemplary Claim: 21
DRWN 4 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 655
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB High precision transmitted navigational data as encrypted data transmitted by global positioning (GPS) satellites is made unavailable in regions designated as hostile and during desired intervals, while allowing the data to be available outside the hostile region. All satellites in the GPS constellation transmit the high precision navigational data in encrypted form. However, only the satellites that are not visible to the hostile region transmit the periodic key necessary to decrypt the data. The periodic key changes after a predetermined time interval. During a given time interval the same key value is used by all satellites for encryption of the high precision navigational data. A receiver can obtain the current periodic key from any visible satellite which is transmitting the periodic key. This key is then used to decrypt the high precision navigational data from that satellite and all other visible satellites. As a result, users in the

hostile region are denied access to the high precision navigational data because they are unable to obtain the periodic key necessary to decrypt the data.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **258278-72-7P**, EM 1926
(preparation of steroids as inhibitors of type 3 3α-hydroxysteroid dehydrogenase)
RN 258278-72-7 USPATFULL
CN Estra-1,3,5(10)-triene-2-carbonitrile, 3,17-dihydroxy-16,16-dimethyl-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 11:26:39 ON 21 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 21 Dec 2003 VOL 139 ISS 26
FILE LAST UPDATED: 19 Dec 2003 (20031219/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all hitstr tot l31

L31 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:116882 HCAPLUS
DN 132:152024
ED Entered STN: 18 Feb 2000
TI Preparation of steroids as inhibitors of type 3 3α-hydroxysteroid dehydrogenase
IN Labrie, Fernand; Merand, Yves; Gauthier, Sylvain; Provencher, Louis; Luu-The, Van
PA Endorecherche, Inc., Can.

greater aromatic hydroxylation but the catecholestrogen was O-methylated to a greater relative extent. The 16β-17β derivative underwent alicyclic as well as substantial aromatic hydroxylation and yielded numerous isomeric glucuronides of O-methylated catechols. Thus, the fluorine exerted complex effects (inhibitory and enhancing) on both localized (D-ring) and distal (A-ring) biotransformations of the estradiol mol.; the direction and magnitude of the effects being dependent upon the stereochem. at C-16 and C-17. These findings provide structural guidelines for restricting the metabolism of tumor-imaging fluoroestrogens and thereby enhancing their delivery to the target tissue.

ST fluoroestradiol prepn metab estrogen receptor imaging

IT Drug metabolism
Imaging agents
Structure-activity relationship
Substituent effects
(metabolism of 16-fluoroestradiols in vivo: chemical strategies for restricting oxidative biotransformations of estrogen-receptor imaging agent)

IT Estrogen receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(metabolism of 16-fluoroestradiols in vivo: chemical strategies for restricting oxidative biotransformations of estrogen-receptor imaging agent)

IT 84693-92-5P 92817-10-2P 92817-11-3P 202397-89-5P 202397-90-8P 202397-91-9P
RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(metabolism of 16-fluoroestradiols in vivo: chemical strategies for restricting oxidative biotransformations of estrogen-receptor imaging agent)

IT 202397-92-0 202397-93-1 202397-94-2 **202397-95-3**
202397-96-4 202397-97-5 202397-98-6 **202397-99-7**
202398-00-3 202398-01-4 202398-02-5 202398-03-6 202398-04-7
202398-05-8 202398-06-9 202398-07-0 202398-08-1
202398-09-2
RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(metabolism of 16-fluoroestradiols in vivo: chemical strategies for restricting oxidative biotransformations of estrogen-receptor imaging agent)

IT 53-16-7, Estrone, reactions 3459-26-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(metabolism of 16-fluoroestradiols in vivo: chemical strategies for restricting oxidative biotransformations of estrogen-receptor imaging agent)

IT 130409-74-4P 130409-84-6P 202397-83-9P 202397-84-0P 202397-85-1P 202397-86-2P 202397-87-3P 202397-88-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(metabolism of 16-fluoroestradiols in vivo: chemical strategies for restricting oxidative biotransformations of estrogen-receptor imaging agent)

RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Abel, S; J Steroid Biochem Mol Biol 1993, V46, P833 HCAPLUS
(2) Bonham, N; J Steroid Biochem Mol Biol 1994, V49, P203 HCAPLUS
(3) Bucala, R; J Steroid Biochem 1986, V25, P127 HCAPLUS
(4) Bush, I; Biochem J 1964, V93, P236 HCAPLUS
(5) Bush, I; J Endocrinol 1962, V24, Pii
(6) Cummins, C; Steroids 1993, V58, P245 HCAPLUS
(7) Dehdashti, F; J Nucl Med 1995, V36, P1766 MEDLINE
(8) Elger, W; Exp Toxicol Pathol 1996, V48, P345

(9) Fishman, J; Annu Rev Physiol 1983, V45, P61 HCAPLUS
(10) French, A; J Label Compound Radiopharm 1991, V30, P431
(11) Gantchev, T; J Med Chem 1994, V37, P4164 HCAPLUS
(12) Hanson, R; Radiopharmaceuticals:Chemistry and Pharmacology 1992, P333
(13) Heiman, D; J Med Chem 1980, V23, P994 HCAPLUS
(14) Jones, E; J Chem Soc Perkin Trans 1 1975, P2308 HCAPLUS
(15) Katzenellenbogen, J; Radiopharmaceuticals:Chemistry and Pharmacology 1992, P297 HCAPLUS
(16) Kiesewetter, D; J Nucl Med 1984, V25, P1212 HCAPLUS
(17) Kiesewetter, D; J Org Chem 1984, V49, P4900 HCAPLUS
(18) Krishnamurthy, S; J Am Chem Soc 1976, V98, P3383 HCAPLUS
(19) Li, P; Steroids 1995, V60, P299 HCAPLUS
(20) Madden, S; Drug Metab Dispos 1996, V24, P469 HCAPLUS
(21) Maggs, J; Biochem Pharmacol 1983, V32, P2793 MEDLINE
(22) Maggs, J; J Steroid Biochem 1983, V19, P1235 HCAPLUS
(23) Maggs, J; J Steroid Biochem Mol Biol 1992, V42, P65 HCAPLUS
(24) McGuire, A; J Nucl Med 1991, V32, P1526 MEDLINE
(25) McOmie, J; Tetrahedron 1968, V24, P2289 HCAPLUS
(26) Mintun, M; Radiology 1988, V169, P45 MEDLINE
(27) Morgan, P; Biochem Pharmacol 1992, V44, P1717 HCAPLUS
(28) Morgan, P; Biochem Pharmacol 1992, V43, P985 HCAPLUS
(29) Nambara, T; Chem Pharm Bull 1971, V19, P2096 HCAPLUS
(30) Nambara, T; J Chromatogr 1971, V60, P418 HCAPLUS
(31) Ohkubo, T; J Steroid Biochem 1990, V36, P501 HCAPLUS
(32) Page, P; Tetrahedron 1990, V46, P2059 HCAPLUS
(33) Patrick, T; J Org Chem 1988, V53, P5153 HCAPLUS
(34) Pelletier, J; Steroids 1994, V59, P536 HCAPLUS
(35) Pfeiffer, D; J Endocrinol 1986, V110, P489 HCAPLUS
(36) Pomper, M; J Med Chem 1990, V33, P3143 HCAPLUS
(37) Poon, G; Drug Metab Dispos 1992, V20, P941 HCAPLUS
(38) Poss, A; J Org Chem 1991, V56, P5962 HCAPLUS
(39) Slikker, W; J Chromatogr 1981, V224, P205 HCAPLUS
(40) Stalford, A; Mol Pharmacol 1994, V45, P1259 MEDLINE
(41) Symes, E; J Steroid Biochem 1985, V22, P155 HCAPLUS
(42) Teitelbaum, P; J Pharmacol Exp Ther 1981, V218, P16 HCAPLUS
(43) Umemoto, T; J Am Chem Soc 1990, V112, P8563 HCAPLUS
(44) Umemoto, T; Org Synth 1990, V69, P129 HCAPLUS
(45) van Brocklin, H; J Nucl Med 1991, V32, P974
(46) van Brocklin, H; Life Sci 1993, V53, P811 HCAPLUS
(47) van Brocklin, H; Nucl Med Biol 1992, V19, P363 HCAPLUS
(48) Wawrzak, Z; J Steroid Biochem 1988, V29, P387 HCAPLUS
(49) Weisman, R; J Label Compound Radiopharm 1991, V31, P426
(50) Williams, K; Steroids 1970, V15, P105 HCAPLUS

IT **202397-95-3 202397-99-7 202398-05-8**
RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(metabolism of 16-fluoroestradiols in vivo: chemical strategies for restricting oxidative biotransformations of estrogen-receptor imaging agent)

RN 202397-95-3 HCAPLUS

CN β-D-Glucopyranosiduronic acid, (16α,17β)-16-fluoro-3,17-dihydroxyestra-1,3,5(10)-trien-2-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 202397-99-7 HCAPLUS
CN β-D-Glucopyranosiduronic acid, (16α,17α)-16-fluoro-3,17-dihydroxyestra-1,3,5(10)-trien-2-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 202398-05-8 HCAPLUS
CN β-D-Glucopyranosiduronic acid, (16β,17β)-16-fluoro-3,17-dihydroxyestra-1,3,5(10)-trien-2-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L31 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1991:43278 HCAPLUS
DN 114:43278
ED Entered STN: 09 Feb 1991
TI Synthesis of 2-hydroxyestriol monoglucuronides and monosulfates
AU Ohkubo, Tadashi; Wakasawa, Tatsuyoshi; Nambara, Toshio
CS Pharm. Inst., Tohoku Univ., Sendai, 980, Japan

SO Steroids (1990), 55(3), 128-32
CODEN: STEDAM; ISSN: 0039-128X
DT Journal
LA English
CC 32-3 (Steroids)
OS CASREACT 114:43278
GI



AB The ring A monoglucuronides I (R = R2 = R3 = H, R1 = II; R = II, R1 = R2 = R3 = H) and monosulfates I (R = SO3H, R1 = R2 = R3 = H; R1 = SO3H, R = R2 = R3 = H) of 2-hydroxyestriol were synthesized from 2-hydroxyestriol 16,17-diacetate I (R = R1 = H, R2 = R3 = Ac) by means of the Koenigs-Knorr reaction with Me α-acetobromoglucuronate and sulfation with sulfur trioxide-pyridine complex, resp., followed by deacetylation. The configuration of these compds. were definitely established by conversion to 2-hydroxyestriol monomethyl esters by methylation, then enzymic hydrolysis. The ring D monoglucuronides I (R = R1 = R2 = H, R3 = II; R = R1 = R3 = H, R2 = II) and monosulfates I (R = R1 = R2 = H, R3 = SO3H; R = R1 = R3 = H, R2 = SO3H) of 2-hydroxyestriol were also prepared from 2-hydroxyestriol, 2,3-dibenzyl ether I (R = R1 = CH2Ph, R2 = R3 = H) by glucuronidation and sulfation in a similar fashion followed by debenzylation. The positions of conjugation were established on the basis of their 1H-NMR spectral data.
ST hydroxyestriol monoglucuronide monosulfate
IT Steroids, compounds
RL: SPN (Synthetic preparation); PREP (Preparation)
(hydroxy, monoglucuronides and monosulfates of hydroxyestriol, preparation of)
IT 21085-72-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with hydroxyestriol diacetate)
IT 111162-88-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(conversion to monoglucuronide or monosulfate)
IT 131429-39-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and conversion to monoglucuronide and monosulfates)
IT 116382-65-1P 131429-36-2P 131429-37-3P 131429-38-4P 131429-40-8P 131429-41-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deacetylation of)
IT 131429-42-0P 131429-43-1P 131429-44-2P 131429-45-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and debenzylation of)
IT 55349-20-7P 55349-21-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and enzymic hydrolysis of)
IT 1236-72-2P 28818-82-8P 55349-18-3P 82356-49-8P 125529-47-7P

125529-48-8P 125529-49-9P 125549-03-3P 131435-34-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT **55349-22-9** 125529-46-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(sequential methylation and alkaline hydrolysis of)
IT **55349-22-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(sequential methylation and alkaline hydrolysis of)
RN 55349-22-9 HCAPLUS
CN β-D-Glucopyranosiduronic acid, (16α,17β)-3,16,17-trihydroxyestra-1,3,5(10)-trien-2-yl (9CI) (CA INDEX NAME)



L31 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1991:722 HCAPLUS
DN 114:722
ED Entered STN: 12 Jan 1991
TI Multiplicity of in vitro glucuronidation of 2-hydroxyestriol
AU Ohkubo, Tadashi; Takahashi, Ayako; Nambara, Toshio
CS Pharm. Inst., Tohoku Univ., Sendai, 980, Japan
SO Journal of Steroid Biochemistry (1990), 36(5), 501-3
CODEN: JSTBBK; ISSN: 0022-4731
DT Journal
LA English
CC 2-4 (Mammalian Hormones)
AB In vitro glucuronidation of 2-hydroxyestriol has been investigated by HPLC with dual-electrode coulometric detection. When incubated with a rat or dog liver microsomal preparation in the presence of UDP glucuronic acid, 2-hydroxyestriol was transformed into the 2-glucuronide together with a small amount of 16- and/or 17-glucuronides. In contrast, incubation of 2-hydroxyestriol with guinea pig liver microsomal preparation yielded the 3-glucuronide and a trace amount of the 2-glucuronide, but no ring D glucuronides. Upon pretreatment with 3-methylcholanthrene, male rat liver exhibited a marked increase in both 2- and 3-glucuronidation activities, whereas female rat liver showed an elevation only in 2-glucuronidation. In both male and female rats, pretreatment with phenobarbital caused a relatively small increase in the glucuronidation activity of the liver. In the male guinea pig, glucuronidation was not affected by pretreatment with either of the two compds. This demonstrated the multiplicity of hepatic 2-hydroxyestriol UDP-glucuronyltransferase in the rat, guinea pig, and dog.
ST hydroxyestriol glucuronidation; UDP glucuronyltransferase catechol estrogen
IT Sex
(hydroxyestriol glucuronidation by liver in relation to)
IT Liver, metabolism
(hydroxyestriol glucuronidation by, sex and species variations in)
IT **55349-22-9** 125529-46-6, 2-Hydroxyestriol 3-monoglucuronide

125529-47-7, 2-Hydroxyestriol 16-monoglucuronide 125529-48-8, 2-Hydroxyestriol 17-monoglucuronide
RL: FORM (Formation, nonpreparative)
(formation of, from 2-hydroxyestriol by liver, sex and species variations in)
IT 1232-80-0, 2-Hydroxyestriol
RL: RCT (Reactant); RACT (Reactant or reagent)
(glucuronidation of, by liver, sex and species variations in)
IT 130731-17-8
RL: BIOL (Biological study)
(of liver, sex and species variations in)
IT **55349-22-9**
RL: FORM (Formation, nonpreparative)
(formation of, from 2-hydroxyestriol by liver, sex and species variations in)
RN 55349-22-9 HCAPLUS
CN β-D-Glucopyranosiduronic acid, (16α,17β)-3,16,17-trihydroxyestra-1,3,5(10)-trien-2-yl (9CI) (CA INDEX NAME)



L31 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1990:112186 HCAPLUS
DN 112:112186
ED Entered STN: 31 Mar 1990
TI Studies on steroids. CCXXXXVI. Separation of isomeric 2-hydroxyestriol monoglucuronides and monosulfates by high-performance liquid chromatography with dual-electrode coulometric detection
AU Ohkubo, Tadashi; Wakasawa, Tatsuyoshi; Shimada, Kazutake; Nambara, Toshio
CS Pharm. Inst., Tohoku Univ., Sendai, 980, Japan
SO Journal of Liquid Chromatography (1989), 12(11), 2093-102
CODEN: JLCHD8; ISSN: 0148-3919
DT Journal
LA English
CC 2-1 (Mammalian Hormones)
AB Separation and selective detection of 2-hydroxyestriol monoglucuronides and monosulfates by HPLC with electrochem. detection on a reversed-phase column were carried out. The effects of composition and pH of mobile phase on the capacity factor were investigated with a Develosil ODS-5 column. Four isomeric monoglucuronides of 2-hydroxyestriol appeared to be separable on this column when 0.5% NaOAc/MeCN was used as a mobile phase. However, 2-hydroxyestriol 2-glucuronide and 16-glucuronide were not satisfactorily resolved. In order to differentiate these 2, the use of a dual-electrode coulometric detector was attempted. 2-Hydroxyestriol ring D glucuronides were selectively detected at the 1st electrode (+0.3 V), while the isomeric ring A glucuronides were detected at the 2nd electrode (+0.9 V). The separation of 4 isomeric monosulfates was similarly attained on a μ-Bondasphere-NH2 column with a 0.1% KH2PO4-THF-MeCN mobile phase.
ST hydroxyestriol glucuronide sulfate chromatog; HPLC hydroxyestriol glucuronide sulfate isomer

IT Chromatography, column and liquid
(high-performance, dual electrode coulometry combined with, of hydroxyestriol monoglucuronide and monosulfate isomers)
IT 55349-18-3, 2-Hydroxyestriol 2-monosulfate **55349-22-9** 82356-49-8, 2-Hydroxyestriol 3-monosulfate 125529-46-6, 2-Hydroxyestriol 3-monoglucuronide 125529-47-7, 2-Hydroxyestriol 16-monoglucuronide 125529-48-8, 2-Hydroxyestriol 17-monoglucuronide 125529-49-9, 2-Hydroxyestriol 17-sulfate 125549-03-3, 2-Hydroxyestriol 16-sulfate
RL: BIOL (Biological study)
(chromatog. separation of, from isomers by HPLC and dual electrode coulometry)
IT 1232-80-0D, 2-Hydroxyestriol, monoglucuronides and monosulfates
RL: BIOL (Biological study)
(isomers, chromatog. separation of, with HPLC and dual electrode coulometry)
IT **55349-22-9**
RL: BIOL (Biological study)
(chromatog. separation of, from isomers by HPLC and dual electrode coulometry)
RN 55349-22-9 HCAPLUS
CN β-D-Glucopyranosiduronic acid, (16α,17β)-3,16,17-trihydroxyestra-1,3,5(10)-trien-2-yl (9CI) (CA INDEX NAME)



L31 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1989:633337 HCAPLUS
DN 111:233337
ED Entered STN: 23 Dec 1989
TI Formylation of estrogens
AU Pert, Derek J.; Ridley, Damon D.
CS Dep. Org. Chem., Univ. Sydney, Sydney, 2006, Australia
SO Australian Journal of Chemistry (1989), 42(3), 405-19
CODEN: AJCHAS; ISSN: 0004-9425
DT Journal
LA English
CC 32-3 (Steroids)
OS CASREACT 111:233337
AB Reimer-Tiemann formylations of estradiol and estrone were investigated and, while substitution was effected under certain conditions to give mixts. of 2- and 4-formyl estrogens, yields were very low and the method was unsuitable for preparative purposes. Regioselective methods were developed and 2-formylestradiol was conveniently prepared from estradiol by formylation of the lithio derivative of the bis(methoxymethyl) ether and removal of the protecting groups with HCl. 4-Formylestradiol was prepared by lithiation of the methoxyethyl ether of 4-bromoestradiol, formylation with HCONMePh, and removal of the protecting group. A number of related derivs., including 2-formylestriol, were prepared
ST formylation estrogen; estradiol formylation; estrone formylation
IT Estrogens
RL: RCT (Reactant); RACT (Reactant or reagent)

(formylation of)
IT Formylation
(of estrogens)
IT 53-16-7, Estrone, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(Reimer-Tiemann formylation of)
IT 113680-59-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(attempted metalation-formylation of)
IT 50-27-1 113680-55-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(formylation of)
IT 1630-83-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(methoxyalkylation of)
IT 123715-92-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deacetylation of)
IT 123715-82-2P 123715-83-3P 123715-90-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and formylation of)
IT 123715-80-0P 123715-91-3P 123746-55-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
IT 99503-86-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of, with Raney nickel)
IT 6599-97-9P 13879-55-5P 13879-56-6P 123715-79-7P 123715-81-1P
123715-84-4P 123715-85-5P 123715-86-6P **123715-87-7P**
123715-88-8P 123715-89-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT **123715-87-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 123715-87-7 HCAPLUS
CN Estra-1,3,5(10)-triene-2-carboxaldehyde, 3,16,17-trihydroxy-, (16α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L31 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1989:154664 HCAPLUS
DN 110:154664
ED Entered STN: 30 Apr 1989
TI Studies on steroids. Part CCXXXIX. Preparation and antigenic properties

of 2-hydroxyestrone-[C-15]-bovine serum albumin conjugate

AU Okubo, Tadashi; Tsuchiko, Fumiko; Wakasawa, Tatsuyoshi; Nambara, Toshio
CS Pharm. Inst., Tohoku Univ., Sendai, 980, Japan

SO Chemical & Pharmaceutical Bulletin (1988), 36(9), 3519-24
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
CC 32-3 (Steroids)
Section cross-reference(s): 6, 15
OS CASREACT 110:154664

GI



I



II

AB A new hapten-carrier conjugate was prepared from 15β-(2-carboxyethylthio)-2-hydroxyestrone (I) by coupling to bovine serum albumin employing the mixed anhydride technique. The specificity of anti-2-hydroxyestrone antiserum elicited in rabbits by immunization with this antigen was assessed by cross-reaction studies with related steroids in the RIA procedure and the results are discussed from the structural point of view. I was prepared from tribromoestrone II in several steps.

ST hydroxyestrone serum albumin conjugate prepn antigen; estrone hydroxy serum albumin conjugate

IT Haptens
RL: RCT (Reactant); RACT (Reactant or reagent)
((carboxyethylthio)hydroxyestrone as)

IT Antigens
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydroxyestrone bovine serum albumin conjugate as)

IT Molecular structure-biological activity relationship
(antigenic, of hydroxyestrone bovine serum albumin conjugate)

IT Albumins, compounds
RL: SPN (Synthetic preparation); PREP (Preparation)
(conjugates, preparation and antigenic activity of)

IT 107-96-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(addition reaction of, with estrenone derivative)

IT 50-27-1, Estriol 50-28-2, Estradiol, preparation 53-16-7, Estrone, preparation 362-05-0, 2-Hydroxyestradiol 362-06-1, 2-Hydroxyestrone 362-08-3, 2-Methoxyestrone 1035-77-4, Estradiol 3-methyl ether 1232-80-0 1474-53-9, Estriol 3-methyl ether 1624-62-0, Estrone methyl ether 3131-23-5, 4-Hydroxyestrone 5976-62-5, 4-Hydroxyestrone 3-methyl

ether 5976-63-6, 2-Hydroxyestrone 3-methyl ether 16105-81-0, 2-Hydroxyestradiol 3-sulfate 26549-41-7, 2-Hydroxyestrone 2-glucuronide 52745-31-0 **55349-22-9** 58562-33-7, 4-Methoxyestrone 89289-97-4 90746-93-3, 4-Hydroxyestrone 3-glucuronide 90746-95-5, 4-Hydroxyestradiol 4-glucuronide 90762-62-2, 4-Hydroxyestrone 4-glucuronide
RL: RCT (Reactant); RACT (Reactant or reagent)
(cross-reactivity of, with anti-hydroxyestrone antiserum)

IT 107-21-1P, 1,2-Ethanediol, preparation
RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(cyclic ketalization by, of tribromoestrone)

IT 79258-15-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclic ketalization of, with ethylene glycol)

IT 119830-38-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and addition reaction of, with mercaptopropionic acid)

IT 119830-41-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and binding of, with bovine serum albumin)

IT 119830-39-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and debromination of)

IT 119830-33-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and dehydrobromination of)

IT 119830-34-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deketalization of)

IT 119830-37-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidation of)

IT 119830-35-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with sodium nitrite)

IT 119830-36-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

IT 119830-40-9P 119830-42-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT **55349-22-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(cross-reactivity of, with anti-hydroxyestrone antiserum)

RN 55349-22-9 HCAPLUS

CN β-D-Glucopyranosiduronic acid, (16α,17β)-3,16,17-trihydroxyestra-1,3,5(10)-trien-2-yl (9CI) (CA INDEX NAME)



L31 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1988:529502 HCAPLUS
DN 109:129502
ED Entered STN: 14 Oct 1988
TI Studies on steroids. CCXXXVI. New synthesis of 2-hydroxyestrogen 2-monoglucuronides
AU Okubo, Tadashi; Tsuchiko, Fumiko; Nambara, Toshio
CS Pharm. Inst., Tohoku Univ., Sendai, 980, Japan
SO Chemical & Pharmaceutical Bulletin (1988), 36(1), 419-23
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
CC 33-3 (Carbohydrates)
Section cross-reference(s): 32
OS CASREACT 109:129502
AB New synthetic routes leading to catechol estrogen 2-monoglucuronides are described. Thus, 4-bromo-2-hydroxyestriol 16,17-diacetate via Koenigs-Knorr reaction with Me α-acetobromoglucuronate in the presence of CdCO3 proceeded preferentially toward the C-2 hydroxyl group. Subsequent reductive dehalogenation followed by alkaline hydrolysis gave the desired 2-hydroxyestriol 2-glucuronide. Similarly, 2-hydroxyestradiol and 2-hydroxyestrone 2-glucuronides were prepared
ST estratriene glucuronide
IT 805-26-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(bromination of)
IT 88623-44-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(periodate oxidation of)
IT 116382-70-8P 116382-71-9P 116436-60-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and enzymic hydrolysis of)
IT 116382-64-0P 116382-67-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenolysis of)
IT 27736-76-1P 53048-13-8P **116408-03-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and methylation of)
IT 116382-62-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and periodate oxidation of)
IT 116382-63-9P 116382-66-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction with glucuronate derivative)
IT 116382-60-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with sodium nitrite)
IT 53048-12-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reactions of)
IT 116382-61-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
IT 116382-65-1P 116382-68-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and saponification of)
IT 5976-63-6P 5976-65-8P 28818-82-8P 116382-69-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT 21085-72-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with steroids)
IT **116408-03-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and methylation of)
RN 116408-03-8 HCAPLUS
CN β-D-Glucopyranosiduronic acid, (16α,17β)-3,16,17-trihydroxyestra-1,3,5(10)-trien-2-yl, monosodium salt (9CI) (CA INDEX NAME)



L31 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1984:68583 HCAPLUS
DN 100:68583
ED Entered STN: 12 May 1984
TI Novel and regiospecific synthesis of 2-amino estrogens via Zincke nitration
AU Numazawa, Mitsuteru; Kimura, Katsuhiko
CS Tohoku Coll. Pharm., Sendai, 983, Japan
SO Steroids (1983), 41(5), 675-82
CODEN: STEDAM; ISSN: 0039-128X
DT Journal
LA English

CC 32-3 (Steroids)
GI



AB Aminoestrogens I (R = H, HO; R1 = HO, R2 = H; R1R2 = O) were prepared Dibromoestrogens II were regiospecifically converted to the 2-nitro-4-bromo derivative III in quant. yields with Zincke nitration using sodium nitrite. Catalytic hydrogenation of III over Pd/C gave directly the desired 2-amino estrogens in high yields. I (R = H, HO; R1 = HO, R2 = H) were also obtained by reduction of the corresponding 2-nitro-4-bromides with NaBH4 in the presence of PdCl2.

ST amino estrogen; Zincke nitration regiochem bromoestrogen

IT Regiochemistry
(of Zincke nitration, of dibromo estrogens)

IT 19-Norsteroids
RL: RCT (Reactant); RACT (Reactant or reagent)
(regioselective Zincke nitration of dibromo estrogens)

IT Nitration
(Zincke, regioselective, of dibromo estrogens)

IT 25975-57-9P 88623-41-0P 88623-42-1P 88623-43-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

IT 6301-87-7P 14984-43-1P 88599-95-5P **88599-96-6P** 88623-44-3P 88623-45-4P 88623-46-5P 88623-47-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT 19590-54-6 19590-55-7 60788-62-7 79258-14-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(regioselective Zincke nitration of)

IT **88599-96-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 88599-96-6 HCAPLUS

CN Estra-1,3,5(10)-triene-3,16,17-triol, 2-amino-, (16α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L31 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1977:463000 HCAPLUS
DN 87:63000
ED Entered STN: 12 May 1984
TI Studies on steroids. Part CXX. Biliary conjugated metabolites of estriol in the rat
AU Nambara, Toshio; Kawarada, Yoshihiko
CS Pharm. Inst., Tohoku Univ., Sendai, Japan
SO Chemical & Pharmaceutical Bulletin (1977), 25(5), 942-8
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
CC 2-2 (Hormone Pharmacology)
Section cross-reference(s): 13
GI



I

AB The conjugated metabolites excreted in rat bile following the oral administration of a large dose of estriol (I) [50-27-1] were isolated and characterized. Eleven principal conjugates were separated by chromatog. on Amberlite XAD-2 resin, followed by gel filtration on Sephadex LH-20 and partition chromatog. on silica gel. The structures of these metabolites were deduced from the physico-chemical data and definitely characterized by preparing their derivs. and comparing them with synthetic specimens. The physiol. significance of biotransformation is discussed.

ST estriol bile conjugate metabolite
IT Bile
(estriol conjugated metabolites of)
IT 1852-50-2 2479-91-6 7219-89-8 17120-96-6 55349-17-2 55349-18-3 55349-19-4 55349-20-7 55349-21-8 **55349-22-9** 55349-23-0
RL: FORM (Formation, nonpreparative)
(formation of, from estriol)
IT 50-27-1
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metabolism of)
IT **55349-22-9**
RL: FORM (Formation, nonpreparative)

(formation of, from estriol)
RN 55349-22-9 HCAPLUS
CN β-D-Glucopyranosiduronic acid, (16α,17β)-3,16,17-trihydroxyestra-1,3,5(10)-trien-2-yl (9CI) (CA INDEX NAME)



L31 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1975:453697 HCAPLUS
DN 83:53697
ED Entered STN: 12 May 1984
TI Conjugated metabolites of estriol in rat bile
AU Nambara, Toshio; Kawarada, Yoshihiko
CS Pharm. Inst., Tohoku Univ., Sendai, Japan
SO Chemical & Pharmaceutical Bulletin (1975), 23(3), 698-700
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
CC 2-2 (Hormone Pharmacology)
Section cross-reference(s): 13
GI For diagram(s), see printed CA Issue.
AB After oral administration of 50 mg of estriol (I) [50-27-1] to the rat, 11 principal conjugates were separated from the bile. The structures of these metabolites were deduced from the physicochem. data and definitely characterized by direct comparison with the synthetic specimens. The significance of the biotransformations observed is discussed.
ST estriol metabolite bile
IT Bile
(estriol metabolites of)
IT 1852-50-2 2479-91-6 7219-89-8 17120-96-6 55349-17-2 55349-18-3 55349-19-4 55349-20-7 55349-21-8 **55349-22-9** 55349-23-0
RL: FORM (Formation, nonpreparative)
(formation of, from estriol)
IT 50-27-1
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metabolism of)
IT **55349-22-9**
RL: FORM (Formation, nonpreparative)
(formation of, from estriol)
RN 55349-22-9 HCAPLUS
CN β-D-Glucopyranosiduronic acid, (16α,17β)-3,16,17-trihydroxyestra-1,3,5(10)-trien-2-yl (9CI) (CA INDEX NAME)

09779331

Welcome to STN International! Enter x:x

LOGINID:ssspta1202sxq

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in DGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	RDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 39	May 16	CHEMREACT will be removed from STN




```
=> d his

     (FILE 'HOME' ENTERED AT 11:00:14 ON 21 DEC 2003)
               SET COST OFF

     FILE 'REGISTRY' ENTERED AT 11:00:25 ON 21 DEC 2003
L1                STR
L2             42 S L1 CSS SAM
L3            949 S L1 CSS FUL
                  SAV L3 QAZI779/A
L4                STR L1
L5            448 S L4 CSS FUL SUB=L3
                  SAV L5 QAZI779A/A
L6            501 S L3 NOT L5
L7                STR L1
L8             25 S L7 CSS FUL SUB=L6
                  SAV L8 QAZI779B/A
L9            476 S L6 NOT L8
L10               STR L7
L11             0 S L10 CSS SAM SUB=L9
L12             0 S L10 SAM SUB=L9
L13             5 S L10 FUL SUB=L9
                  SAV L13 QAZI779C/A
L14               STR L10
L15             0 S L14 SAM SUB=L9
L16             3 S L14 FUL SUB=L9
                  SAV L16 QAZI779D/A

     FILE 'HCAOLD' ENTERED AT 11:19:10 ON 21 DEC 2003
L17             0 S L16

     FILE 'HCAPLUS' ENTERED AT 11:19:12 ON 21 DEC 2003
L18             3 S L16

     FILE 'USPATFULL, USPAT2' ENTERED AT 11:19:24 ON 21 DEC 2003
L19             1 S L16

     FILE 'HCAPLUS' ENTERED AT 11:19:36 ON 21 DEC 2003
L20          5842 S L6
L21          5811 S L9
L22            16 S L20,L21 AND (AGOSTON ? OR PRIBLUDA ? OR TRESTON ? OR GREEN ?)
L23             2 S L20,L21 AND ENTREMED?/PA,CS
L24            16 S L22,L23
                  SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 11:21:45 ON 21 DEC 2003
L25            23 S E1-E23
```

```
L26          15 S L25 AND METHOXY
L27           8 S L25 NOT L26

     FILE 'REGISTRY' ENTERED AT 11:25:32 ON 21 DEC 2003

     FILE 'HCAOLD' ENTERED AT 11:26:04 ON 21 DEC 2003
L28           0 S L13

     FILE 'USPATFULL, USPAT2' ENTERED AT 11:26:14 ON 21 DEC 2003
L29           0 S L13

     FILE 'HCAPLUS' ENTERED AT 11:26:18 ON 21 DEC 2003
L30           8 S L13
L31          11 S L30,L18

     FILE 'USPATFULL, USPAT2' ENTERED AT 11:26:30 ON 21 DEC 2003

     FILE 'HCAPLUS' ENTERED AT 11:26:39 ON 21 DEC 2003

=>
```

3/8 - (C) FILE HCAPLUS
STN CA Caesar accession number : 1600
AN - 1990:152537 HCAPLUS
DN - 112:152537
TI - Kits for RIA of catechol estrogens for breast cancer diagnosis
IN - Kubodera, Akiko
PA - Research Development Corp. of Japan, Japan
SO - Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT - Patent
LA - Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PN -	JP63090763	A	19880421	JP 1986-235647	19861003
	JP2517561B	B	19960724		

OS - MARPAT 112:152537
AB - A kit for immunoassay of catechol estrogens consists of antibodies to I (A = :NO, O2C; n = 1-4; R = protein residue; R1, R2 = H, OH) and labeled catechol estrogens. 2,3-Dihydroxyestra-1,3,5(10)-trien-17-one was treated with carboxymethylhydroxylamine-HCl to give 2-hydroxyestrone-17-(o-carboxymethyl)oxium, which was bound to bovine serum albumin for use in antibody (antiserum) prodn. A kit for 2-hydroxyestrone detn. consisted of this antibody and 2-hydroxyestrone-3H.
GI -

[00000018]

IT ***120858-24-4***
RL: BIOL (Biological study)
(RIA kit contg., for catechol estrogen detn.)
RN 120858-24-4 HCAPLUS
CN Estra-1,3,5(10)-triene-2,3,4-triol, labeled with tritium (9CI) (CA INDEX NAME)

Absolute stereochemistry.
[00000019]

IT ***120858-21-1*** , Estra-1,3,5(10)-triene-2,3,4-triol
RL: ANT (Analyte); ANST (Analytical study)
(detn. of, RIA kit for)
RN 120858-21-1 HCAPLUS
CN Estra-1,3,5(10)-triene-2,3,4-triol (9CI) (CA INDEX NAME)

Absolute stereochemistry.
[00000020]

XP-002186128

4/5/1
DIALOG(R)File 399:CA SEARCH(R)

109110741 CA: 109(13)110741u PATENT
11.beta.-(4-Isopropenylphenyl)estra-4,9-dienes, procedure for their preparation, pharmaceutical preparations containing them, and their use as antigestagens
INVENTOR(AUTHOR): Ottow, Eckhard; Wiechert, Rudolf; Neef, Guenter; Beier, Sybille; Elger, Walter; Henderson, David
LOCATION: Fed. Rep. Ger.
ASSIGNEE: Schering A.-G.
PATENT: Germany Offen. ; DE 3625315 A1 DATE: 880128
APPLICATION: DE 3625315 (860725)
PAGES: 5 pp. CODEN: GWXXBX LANGUAGE: German CLASS: C07J-001/00A; C07C-041/00B; A61K-031/565B; A61K-031/57B; A61K-031/575B
SECTION:
CA232003 Steroids
CA202XXX Mammalian Hormones
IDENTIFIERS: progesterone antagonist estradiene prepn, antigestagen estradiene prepn
DESCRIPTORS:
Progestogens...
inhibitors, estradiene derivs.
Steroids,preparation...
prepn. of estradienes as antigestagens
CAS REGISTRY NUMBERS:
57-83-0 biological studies, antagonists to, estradiene derivs. as
93697-60-0 Grignard reaction of, with bromoisopropenylbenzene
6888-79-5 Grignard reaction of, with epoxyestrenol deriv.
116196-34-0P 116229-17-5P prepn. and reaction of, in synthesis of antigestagenic estradiene deriv.
116196-21-5P 116196-22-6P 116196-23-7P 116196-24-8P 116196-25-9P 116196-26-0P 116196-27-1P 116196-28-2P 116196-29-3P 116196-30-6P 116196-31-7P 116196-32-8P prepn. of, as antigestagen

8/5/7
DIALOG(R)File 399:CA SEARCH(R)

74010081 CA: 74(3)10081u JOURNAL
Orally active long-acting estrogen (AY-20,121)
(3-(2-propynyloxy)-estra-1,3,5(10)-trien-17.beta.-ol trimethylacetate)
AUTHOR(S): Banik, Upendra K.; Revesz, Clara; Herr, Ferenc
LOCATION: Ayerst Res. Lab., Montreal, Que.
JOURNAL: Steroids DATE: 1970 VOLUME: 16 NUMBER: 3 PAGES: 289-96
CODEN: STEDAM LANGUAGE: English
SECTION:
CA804000 Hormones and Related Substances
IDENTIFIERS: estrogens synthetic, contraceptives steroids
DESCRIPTORS:
Estrogenic hormones...
(propynyloxy)estratrienol trimethylacetate
Vagina...
(propynyloxy)estratrienol trimethylacetate effect on epithelium of
CAS REGISTRY NUMBERS:
57-63-6 152-43-2 biol. activity of, (propynyloxy)estratrienol trimethylacetate in relation to
28002-65-5 estrogenic hormone

8/5/8
DIALOG(R)File 399:CA SEARCH(R)

73056310 CA: 73(11)56310a PATENT
Rodenticidal 3-(2-propynyloxy)-estra-1,3,5(10)-trien-17.beta.-ol pivalate
INVENTOR(AUTHOR): Kruger, Gunther
ASSIGNEE: American Home Products Corp.
PATENT: United States US 3496272 DATE: 700217
APPLICATION: United States DATE: 680123
PAGES: 3 pp. CODEN: USXXAM CLASS: 424-238; A 01n
SECTION:
CA832000 Steroids
IDENTIFIERS: rodenticidal propynyloxy estratrienols
DESCRIPTORS:
19-Norsteroids...
17-hydroxy-3-(2-propynyloxy) pivalate

CAS REGISTRY NUMBERS:
24099-40-9P 24894-50-6P 28002-65-5P 28151-61-3P 28275-48-1P
28275-49-2P 28275-50-5P 28425-85-6P prepn. of

8/5/9
DIALOG(R)File 399:CA SEARCH(R)

72032135 CA: 72(7)32135a PATENT
3-Alkoxy-17.alpha.-propynylestra-1,3,5(10)-trien-17.beta.-ols
INVENTOR(AUTHOR): Galantay, Eugene E.
ASSIGNEE: Sandoz Ltd.
PATENT: Germany Offen. DE 1907330 DATE: 691023
APPLICATION: United States DATE: 680219
PAGES: 20 pp. CODEN: GWXXBX CLASS: C 07c; A 61k
SECTION:
CA832000 Steroids
IDENTIFIERS: estratrienols propynyl
DESCRIPTORS:
19-Norsteroids...
3-alkoxy
CAS REGISTRY NUMBERS:
24640-01-5P 24640-02-6P 24640-03-7P 24640-04-8P prepn. of